To require the Department of Health and Human Services to release documents, communications, and other information relating to most favored nation pricing agreements and other private or confidential drug pricing deals struck with manufacturers, and for other purposes.
Summary
HR9699, introduced by Rep. Chu (D-CA), would force HHS to publicly release confidential drug pricing agreements, including most-favored-nation deals. The bill is in early stage (referred to three committees) with 23 Democratic cosponsors. If enacted, it would increase pricing transparency, pressuring drug manufacturers ($JNJ, $LLY) and PBMs ($UNH) by exposing proprietary discount structures. Near-term market impact is low due to legislative hurdles.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR9699 is an early-stage transparency bill with no Republican cosponsors, making passage unlikely in the current Congress.
- 2.If enacted, the bill would expose confidential drug pricing deals, pressuring net prices for manufacturers like $JNJ and $LLY and PBM margins for $UNH.
- 3.No direct market impact expected in the near term; the bill serves as a legislative signal for future drug pricing reform.
Market Implications
The bill's introduction has no immediate market impact given its early stage and partisan sponsorship. However, it adds to the growing legislative pressure on drug pricing transparency. For and $LLY, any future advancement of this bill could create headwinds for their pharmaceutical pricing power. For , the PBM transparency angle could compound existing regulatory scrutiny on pharmacy benefit managers. Investors should watch for committee markups or a companion Senate bill as catalysts.
Full Analysis
On July 15, 2026, Rep. Judy Chu (D-CA) introduced HR9699, a bill requiring the Department of Health and Human Services to disclose documents, communications, and information related to most-favored-nation pricing agreements and other confidential drug pricing deals with manufacturers. The bill has been referred to the Committees on Energy and Commerce, Ways and Means, and the Budget — a typical path for healthcare pricing legislation. With 23 Democratic cosponsors and no Republican support, the bill faces an uphill battle in the Republican-controlled House. It is in the earliest legislative stage; no hearings or markups have occurred.
The money trail: HR9699 does not authorize or appropriate any funding. Its mechanism is purely informational — mandating transparency. The economic impact would come from the downstream effects of exposed pricing data: manufacturers and PBMs would lose negotiating leverage, potentially leading to lower net drug prices in federal programs (Medicare Part D, Medicaid, VA, DoD). This could reduce revenue for drug companies and squeeze PBM margins, but the magnitude depends on how aggressively the disclosed data is used in future negotiations.
Convergence: No related presidential actions or other signals directly connect to this bill. The recent presidential proclamation on chemical manufacturing regulatory relief is unrelated to drug pricing. This bill stands alone as a transparency push.
Structural winners and losers: The primary losers are drug manufacturers with significant federal program exposure and PBMs that negotiate confidential rebates. (pharma segment ~55% of $85.2B revenue) and $LLY (diabetes/obesity drugs ~70% of $34.1B revenue) are most exposed among the provided tickers. $UNH's Optum Rx PBM would face margin pressure. Winners would be taxpayers and government payers, but no public company directly benefits from this bill.
Timeline: The bill is at the referral stage. Given the partisan divide and early stage, passage in the 119th Congress is unlikely. However, the issue of drug pricing transparency has bipartisan appeal in principle, so the bill could serve as a marker for future negotiations. Investors should monitor committee activity and any companion bill in the Senate.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Mandatory disclosure of confidential most-favored-nation pricing agreements and other drug pricing deals between HHS and manufacturers.
Who must act
HHS — must release documents, communications, and information related to drug pricing agreements with manufacturers.
What happens
Exposure of Lilly's pricing and rebate structures for key products (e.g., Mounjaro, Zepbound, Trulicity) in federal programs, reducing pricing opacity and potentially enabling more aggressive government negotiation.
Stock impact
Lilly's revenue is heavily concentrated in diabetes and obesity drugs (over 70% of $34.1B FY2025 revenue). These products face intense competition and rely on confidential rebates for formulary placement. Transparency could compress net prices, especially for high-list-price drugs. A 1-2% net price reduction would impact revenue by $341M-$682M.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Ending Birth Tourism
This executive order directs the Secretaries of State and Homeland Security to prevent foreign nationals from entering the U.S. on nonimmigrant visas for the purpose of giving birth (birth tourism), including revoking visas, barring entry, and taking action against facilitators. It defines birth tourism as entry via nonimmigrant visa for childbirth and allows humanitarian or national interest exemptions.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →